

NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project

Jessica L. Petrick¹, Vikrant V. Sahasrabudhe^{1,2,3}, Andrew T. Chan^{4,5}, Michael C. Alavanja¹, Laura E. Beane-Freeman¹, Julie E. Buring^{4,6}, Jie Chen¹, Dawn Q. Chong^{5,7}, Neal D. Freedman¹, Charles S. Fuchs⁸, John Michael Gaziano^{4,9}, Edward Giovannucci⁶, Barry I. Graubard¹, Albert R. Hollenbeck¹⁰, Lifang Hou¹¹, Eric J. Jacobs¹², Lindsay Y. King^{4,5}, Jill Koshiol¹, I-Min Lee^{4,6}, Martha S. Linet¹, Julie R. Palmer¹³, Mark P. Purdue¹, Lynn Rosenberg¹³, Catherine Schairer¹, Howard D. Sesso^{4,6}, Alice J. Sigurdson¹, Jean Wactawski-Wende¹⁴, Anne Zeleniuch-Jacquotte¹⁵, Peter T. Campbell¹², and Katherine A. McGlynn¹

Abstract

Chronic inflammation plays a pivotal role in the pathogenesis of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), the two most common types of liver cancer. A number of prior experimental studies have suggested that nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin and ibuprofen, may potentially protect against liver cancer. However, no observational study has examined the association between aspirin duration and dose or other over-the-counter non-aspirin NSAIDs, such as ibuprofen, and liver cancer incidence. Furthermore, the association between NSAID use and risk of ICC is unclear. As part of the Liver Cancer Pooling Project, we harmonized data on 1,084,133 individuals (HCC = 679, ICC = 225) from 10 U.S.-based prospective cohort studies. Cox proportional hazards regression models were used to evaluate multivariable-adjusted HRs and 95% confidence

intervals (CI). Current aspirin use, versus nonuse, was inversely associated with HCC (HR, 0.68; 95% CI, 0.57–0.81), which persisted when restricted to individuals not using non-aspirin NSAIDs and in a 5- and 10-year lag analysis. The association between aspirin use and HCC risk was stronger for users who reported daily use, longer duration use, and lower dosage. Ibuprofen use was not associated with HCC risk. Aspirin use was associated with a reduced ICC risk in men (HR, 0.64; 95% CI, 0.42–0.98) but not women (HR, 1.34; 95% CI, 0.89–2.01; $P_{\text{interaction}} = 0.01$). The observed inverse association between aspirin use and liver cancer in our study, together with previous data, suggests the merit of future intervention studies of aspirin and other agents that affect chronic inflammatory pathways for HCC and possibly ICC. *Cancer Prev Res*; 8(12); 1156–62. ©2015 AACR.

¹Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland. ²Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland. ³Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee. ⁴Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. ⁵Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. ⁶Department of Epidemiology, Harvard School of Public Health, Boston, MA. ⁷Division of Medical Oncology, National Cancer Centre Singapore, Singapore. ⁸Department of Medicine, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. ⁹VA Boston Healthcare System, Brockton, Massachusetts. ¹⁰AARP, Washington, District of Columbia (retired). ¹¹Department of Preventive Medicine, Northwestern University, Chicago, Illinois. ¹²Epidemiology Research Program, American Cancer Society, Atlanta, Georgia. ¹³Sloan Epidemiology Center at Boston University, Boston, Massachusetts. ¹⁴Department of Epidemiology and Environmental Health, University at Buffalo, Buffalo, New York. ¹⁵Department of Population Health, New York University School of Medicine, New York.

Note: Supplementary data for this article are available at Cancer Prevention Research Online (<http://cancerprevres.aacrjournals.org/>).

J.L. Petrick and V.V. Sahasrabudhe should be regarded as joint first authors.

Corresponding Author: Jessica L. Petrick, National Cancer Institute, 9609 Medical Center Drive, 7E-232, Bethesda, MD 20892. Phone: 240-276-7321; Fax: 240-276-7838; E-mail: jessica.petrick@nih.gov

doi: 10.1158/1940-6207.CAPR-15-0126

©2015 American Association for Cancer Research.

Introduction

Primary liver cancer has a 5-year survival rate of approximately 17% (1). This malignancy is the second leading cause of cancer death worldwide (2) and the seventh leading cause in the United States (U.S.; ref. 3). Since 1980, primary liver cancer rates have been increasing (4, 5) and have been among the most rapidly increasing cancer types in the U.S. and other Western countries (6). In addition to poor survival and increasing incidence, primary liver cancer is characterized by aggressive growth, lack of effective screening or early detection methods, and high rates of metastases. Thus, developing preventive strategies for reducing the substantial disease burden associated with primary liver cancers is of considerable clinical and public health importance (5, 7, 8).

There are two major histologic types of primary liver cancer: hepatocellular carcinoma (HCC), which is the dominant histologic type of liver cancer in the United States and accounts for approximately 75% of cases, and intrahepatic cholangiocarcinoma (ICC), which is the second most common histologic type and accounts for approximately 12% of cases. The other 13% of cases are rare tumor types (e.g., hepatoblastoma and sarcoma) or poorly specified (9). Risk factors for HCC include chronic hepatitis B or C virus (HBV or HCV) infection, excessive levels of alcohol consumption, aflatoxin exposure, obesity, and diabetes

(10). While ICC is commonly associated with primary sclerosing cholangitis, and inflammatory bowel diseases, a recent meta-analysis identified potential common risk factors for HCC and ICC, such as chronic HBV and HCV infection, excessive alcohol consumption, diabetes, and obesity (11).

Chronic inflammation is a common feature underlying the etiology of both HCC and ICC (12, 13). Nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin and ibuprofen, are potential chemopreventive agents for primary liver cancer. Observational studies and clinical trials have reported inverse associations between aspirin use and incidence of gastrointestinal tract cancers (14–19). *In vivo* and *in vitro* studies (20–22) and two observational studies (23, 24) suggest similar inverse associations for primary liver cancer. However, associations between duration or dosage of aspirin use and liver cancer risk, or with commonly used "over-the-counter" (OTC) non-aspirin NSAIDs (e.g., ibuprofen) have not been previously described. Furthermore, possible associations between NSAIDs and ICC have not been studied. Therefore, we conducted a study of pooled data from 10 U.S.-based prospective cohort studies to examine associations of aspirin and OTC non-aspirin NSAIDs (i.e., ibuprofen) with HCC and ICC.

Materials and Methods

Study population

The Liver Cancer Pooling Project (LCPP) has been described previously (25). Briefly, all U.S.-based cohort studies that are members of the National Cancer Institute (NCI) Cohort Consortium were invited to participate in the LCPP. Of the 14 studies that agreed to participate, 10 studies contributed data on both NSAID use and liver cancer histology (Supplementary Table S1).

Outcomes

While follow-up times varied by parent study, participants in the LCPP were followed-up for outcomes for an average of 11.9 years. Incident primary liver cancer cases [defined as International Classification of Diseases, 10th edition [ICD-10] diagnostic code C22] among LCPP cohort participants were ascertained by various methods, depending on the parent cohort: linkage to state cancer registries, medical record review, National Death Index linkage, or a self-report to the parent cohort study. Cases missing histology information were excluded ($n = 840$). Cases were then classified as HCC [International Classification of Diseases for Oncology, 3rd edition [ICD-O-3] histology codes of 8170–8175] or ICC (ICD-O-3 histology codes of 8032–8033, 8041, 8050, 8070–8071, 8140–8141, 8160, 8260, 8480, 8481, 8490, and 8560). Cases with all other histology codes were excluded from the primary analysis ($n = 225$). Finally, individuals with missing aspirin information were excluded from the analytic cohort (HCC, $n = 285$; ICC, $n = 71$; non-case $n = 303,119$). Thus, the current study included 679 HCC cases, 225 ICC cases, and 1,083,229 non-cases.

Exposure assessment

With the exception of BWHS, self-reported questionnaires collected information on use of both aspirin and non-aspirin NSAIDs, either currently or during the previous year (Supplementary Table S2). Four studies (AHS, USRT, PLCO, and CPSII) specifically asked about ibuprofen use. Five studies (NIH-AARP, BCDDP, PLCO, CPSII, WHI) asked about frequency of aspirin use (categorized as nonuser, less than daily, daily, and more than

daily), and five studies (AHS, BCDDP, CPSII, BWHS, WHI) also asked about duration (categorized as nonuser, <5, and ≥ 5 years of aspirin use). Two studies (CPSII and WHI) ascertained absolute dose (categorized as nonuser, <163, and ≥ 163 mg). NSAID use was ascertained at baseline or first follow-up questionnaire for all cohorts.

Statistical analysis

Cox proportional hazard regression analysis was used to calculate adjusted HRs and 95% confidence intervals (CI) for the associations of aspirin or ibuprofen use with HCC and ICC risk, using follow-up time as the underlying time metric. The proportional hazards assumption was tested using an interaction term between aspirin or ibuprofen (defined as current use vs. nonusers) and log(time) in models that included confounders. The proportional hazards assumption was not observed to be violated ($P \geq 0.05$).

Effect measure modification by sex, cigarette smoking [evaluated as never/former/current and cigarettes/d (continuous)], alcohol consumption [evaluated as ever/never and drinks/d (continuous)], self-reported history of diabetes, and ibuprofen use was assessed using likelihood ratio tests comparing regression models with and without a multiplicative term (26).

Potential confounders (27) were examined to determine whether they were associated with (i) the exposure in the general population (i.e., entire cohort), using a logistic regression model and (ii) the outcome among the unexposed (i.e., non-NSAID users), using a Cox proportional hazards regression, by examining the magnitude of association (28). If a potential confounder was associated with the exposure and outcome, then the full model was then evaluated both with and without the covariate of interest. If the covariate significantly contributed to the full model ($P < 0.05$), it was retained for the final model (29, 30); age at questionnaire administration (years, continuous), sex [male/female], race [Caucasian, African American, Asian/Pacific Islander, American Indian/Alaskan Native, other], smoking (never/current/former), alcohol consumption [categorized drinks/d (0, >0–<1, 1–3, >3)], self-reported history of diabetes (yes/no), and self-reported or directly measured body mass index (BMI; kg/m², continuous) met this criterion and were included in all final models. We adjusted for parent study in all models using fixed study effects. We also used fixed-effects meta-analysis to estimate a summary HR and assess heterogeneity using I^2 . An I^2 of 0% indicates no heterogeneity, whereas larger values indicate increasing heterogeneity between studies (31). Analyses were conducted using SAS version 9.3 (SAS Institute) and STATA version 13 (StataCorp LP). All P values are two-sided.

Nested case-control study of HBV/HCV

As individuals with HBV/HCV infection are at the highest risk of developing chronic liver disease, they are often advised to stop taking NSAIDs. Thus, we wanted to examine whether our results could further be confounded by HBV/HCV status. However, serum samples were not available from all persons, so a nested case-control analysis was conducted. At time of diagnosis, all cases with serum were matched to non-cases (controls) with serum on age, race/ethnicity, sex, date of baseline blood collection, and parent study. Age and date of blood draw were matched within 2 months. Within this nested case-control study, conditional logistic regression was used to examine potential

confounding by HBV and HCV, adjusting for BMI, smoking, alcohol, and history of diabetes.

To determine HBV status, hepatitis B surface antigen (HBsAg) was assayed using the Bio-Rad GS HBsAg 3.0 enzyme immunoassay (Bio-Rad Laboratories). HBsAg is a marker of active HBV infection and the marker on which HBV carrier status is based. To determine HCV status, antibody to hepatitis C virus (anti-HCV) was assessed using the Ortho HCV Version 3.0 ELISA test system (Ortho-Clinical Diagnostics, Inc.). A positive anti-HBV test indicates that the person is, or was, infected with HCV. Current HCV infection can be confirmed via determination of HCV RNA. As the correlation between anti-HCV positivity and HCV RNA positivity is high, the current study elected not to incur the additional costs of running the confirmatory tests.

Sensitivity analyses

To reduce the potential influence of concurrent exposure to non-aspirin NSAIDs, we examined aspirin use among individuals who did not use ibuprofen or other non-aspirin NSAIDs. Next, to evaluate whether the associations were entirely driven by the inverse associations previously reported in the NIH-AARP cohort (24), we repeated analyses after excluding this study. As a sensitivity analysis for duration of aspirin use, we conducted a lag analysis, excluding cases that developed within the first 5 or 10 years of follow-up by delaying the start of follow-up for all participants. Finally, we analyzed all confirmed or suspected HCC cases, which included HCC cases (ICD-O-3 histology codes of 8170–8175) and additional suspected HCC cases defined as ICD-O-3 histology codes of 8000, 8010, or missing.

Results

Demographic characteristics of aspirin users and nonusers at baseline are shown in Table 1. Forty-four percent of the participants reported current aspirin use. Compared with nonusers of aspirin, aspirin users were more likely to be men, white, overweight (BMI > 25), heavy drinkers (>3 drinks/d), nonsmokers, and report a history of diabetes.

Current aspirin use was associated with a 32% reduction in risk of HCC, compared with participants who did not use aspirin (HR, 0.68; 95% CI, 0.57–0.81; Table 2), and studies were homogeneous ($I^2 = 0\%$, $P = 0.8$). Results were similar when restricted to people who did not use other non-aspirin NSAIDs (HR, 0.63; 95% CI, 0.50–0.78). Less than once daily or once daily aspirin use was associated with an approximately 35% and 32% reduction of HCC risk (HR, 0.65; 95% CI, 0.51–0.82 and HR, 0.68; 95% CI, 0.53–0.87, respectively). However, no association was observed among participants who used aspirin more than once a day. Longer duration of aspirin use (≥ 5 years) was associated with a nonsignificantly greater decreased HR of HCC than shorter duration (<5 years; HR, 0.70; 95% CI, 0.42–1.16 and HR, 0.84; 95% CI, 0.49–1.44). Associations were stronger among those taking low-dose aspirin (<163 mg; HR, 0.39; 95% CI, 0.17–0.91) than higher dose aspirin (≥ 163 mg; HR, 0.67; 95% CI, 0.42–1.08), although we had small case numbers for these analyses. In contrast to aspirin, ibuprofen use was not associated with HCC risk (HR, 1.01; 95% CI, 0.72–1.42). However, when ibuprofen use was restricted to nonusers of aspirin and other NSAIDs, a nonsignificant decreased risk of HCC was noted (HR, 0.78; 95% CI,

Table 1. Characteristics of participants in the LCCP by current aspirin use

	Aspirin nonusers (N = 606,663) n (%)	Aspirin users (N = 477,470) n (%)
Outcome		
Non-cases	606,179 (99.92)	477,050 (99.91)
HCC	364 (0.06)	315 (0.07)
ICC	120 (0.02)	105 (0.02)
Age at entry, y		
<50	124,428 (20.51)	55,624 (11.65)
50–59	178,233 (29.38)	141,274 (29.59)
60–69	228,897 (37.73)	224,413 (47.00)
≥ 70	75,076 (12.38)	56,152 (11.76)
Missing	29	7
Sex		
Male	161,777 (26.67)	227,231 (47.59)
Female	444,886 (73.33)	250,239 (52.41)
Race		
White	500,570 (83.10)	441,925 (93.06)
Black	73,601 (12.22)	18,198 (3.83)
Asian/Pacific Islander	11,780 (1.96)	4,034 (0.85)
American Indian/Alaskan Native	1,266 (0.21)	881 (0.19)
Other	15,129 (2.51)	9,847 (2.07)
Missing	4,317	2,585
BMI, kg/m ²		
<18.5	7,502 (1.28)	4,530 (0.97)
18.5–24.9	251,394 (42.77)	183,585 (39.17)
25–29.9	208,682 (35.50)	187,999 (40.12)
≥ 30	120,262 (20.46)	92,516 (19.74)
Missing	18,823	8,840
Diabetes		
No	568,533 (94.72)	440,926 (92.70)
Yes	31,674 (5.28)	34,697 (7.30)
Missing	6,456	1,847
Alcohol (drinks/d)		
Nondrinker	161,511 (28.27)	97,688 (21.69)
>0–<1 drink	322,465 (56.44)	253,415 (56.27)
1–3 drinks	68,445 (11.98)	72,060 (16.00)
>3 drinks	18,957 (3.32)	27,228 (6.05)
Missing	35,285	27,079
Cigarette smoking status		
Never smoker	300,077 (50.32)	192,369 (40.97)
Former smoker	205,550 (34.47)	197,922 (42.15)
Current smoker	90,668 (15.21)	79,251 (16.88)
Missing	10,368	7,928

0.45–1.38). For overall ICC, no association was observed for either aspirin or ibuprofen use (HR, 0.94; 95% CI, 0.70–1.27 and HR, 1.17; 95% CI, 0.64–2.15, respectively).

Table 3 shows sensitivity analyses after excluding the NIH-AARP cohort, for which an association between aspirin and liver cancer was previously shown, and a 5- and 10-year lag-analysis. When then NIH-AARP cohort was excluded from the analysis, current aspirin remained inversely associated with HCC risk—both overall (HR, 0.72; 95% CI, 0.57–0.90) and when restricted to nonusers of other NSAIDs (HR, 0.66; 95% CI, 0.50–0.86). Similar results were found in the 5-year lag analysis (overall HR, 0.75; 95% CI, 0.60–0.94 and nonuser of other NSAIDs HR, 0.62; 95% CI, 0.46–0.82). Results were consistent in the 10-year lag analysis, but sample size was small.

As shown in Supplementary Table S3, there was some evidence of a multiplicative interaction between aspirin use and sex and history of diabetes for ICC ($P = 0.01$ and $P = 0.01$, respectively) but not for HCC ($P = 0.9$ and $P = 0.1$, respectively). Among men, current aspirin users had 36% lower risk of ICC (HR, 0.64; 95% CI, 0.42–0.98) than nonusers. Whereas no association was

Table 2. Adjusted HR and 95% CI for associations between NSAID use and HCC and ICC incidence, LCCP

	HCC			ICC		
	Cases	Person-years	HR (95% CI)	Cases	Person-years	HR (95% CI)
Aspirin use						
Nonuser	313	6,686,327	1.0 (—)	105	6,684,656	1.0 (—)
Any current use	368	5,037,223	0.68 (0.57–0.81)	95	5,035,905	0.94 (0.70–1.27)
Frequency of use, average times per day						
Nonuser	196	2,335,809	1.0 (—)	54	2,334,914	1.0 (—)
Less than once daily	112	1,658,658	0.65 (0.51–0.82)	38	1,658,171	0.82 (0.53–1.27)
Once daily	92	951,535	0.68 (0.53–0.87)	24	951,104	0.80 (0.49–1.31)
More than once daily	20	249,938	0.92 (0.58–1.46)	9	249,869	1.59 (0.78–3.23)
Duration of use, y						
Nonuser	56	1,164,323	1.0 (—)	15	1,163,940	1.0 (—)
<5	18	341,066	0.84 (0.49–1.44)	5	340,939	0.84 (0.30–2.41)
≥5	21	497,395	0.70 (0.42–1.16)	10	497,284	1.27 (0.56–2.89)
Dosage of aspirin, mg						
Nonuser	89	1,887,651	1.0 (—)	42	1,887,342	1.0 (—)
<163	6	197,820	0.39 (0.17–0.91)	4	197,816	0.95 (0.33–2.70)
≥163	23	518,242	0.67 (0.42–1.08)	12	518,168	1.08 (0.56–2.08)
Aspirin use, restricted to nonusers of other NSAIDs						
Nonuser	223	4,743,276	1.0 (—)	70	4,741,957	1.0 (—)
Any current use	142	3,236,674	0.63 (0.50–0.78)	56	3,235,969	1.08 (0.74–1.57)
Ibuprofen use						
Nonuser	150	2,534,499	1.0 (—)	42	2,533,705	1.0 (—)
Any current use	46	1,092,098	1.01 (0.72–1.42)	15	1,091,857	1.17 (0.64–2.15)
Ibuprofen use, restricted to nonusers of aspirin and other NSAIDs						
Nonuser	87	1,411,196	1.0 (—)	21	1,410,729	1.0 (—)
Any current use	15	485,570	0.78 (0.45–1.38)	7	485,522	1.51 (0.63–3.64)

NOTE: Adjusted for: sex, age (continuous), race (white, black, Asian/Pacific Islander, American Indian/Alaskan Native, other), cohort (AARP, AHS, USRT, PLCO, HPFS, CPSII, IWHS, BWHS, WHI, NHS), BMI (continuous), smoking status (nonsmoker, former smoker, current smoker), alcohol (nondrinker, and >0–<1, 1–3, >3 drinks/d), and history of diabetes (yes/no).

observed in women (HR, 1.34; 95% CI, 0.89–2.01). There was also some evidence of a multiplicative interaction between aspirin use and ibuprofen use for HCC ($P = 0.09$) but not ICC ($P = 0.7$). However, sample size was limited. We also observed generally similar findings when we expanded our HCC case definition to

include suspected but not histologically confirmed HCC cases (Supplementary Table S4).

Among the HCC cases tested ($n = 158$), 42 (26.6%) were positive for anti-HCV and 5 (3.2%) were positive for HBsAg. Among the matched controls ($n = 397$), 10 (2.5%) were positive

Table 3. Adjusted HR and 95% CI for associations between aspirin use and HCC and ICC incidence; sensitivity analysis excluding the NIH-AARP cohort and lag-analysis, LCCP

	HCC			ICC		
	Cases	Person-years	HR (95% CI)	Cases	Person-years	HR (95% CI)
Excluding the NIH-AARP cohort						
Aspirin use						
Nonuser	220	5,977,872	1.0 (—)	81	5,976,554	1.0 (—)
Any current use	126	3,492,787	0.72 (0.57–0.90)	49	3,492,031	0.98 (0.68–1.42)
Aspirin use, restricted to nonusers of other NSAIDs						
Nonuser	173	4,392,942	1.0 (—)	60	4,391,840	1.0 (—)
Any current use	86	2,584,988	0.66 (0.50–0.86)	37	2,584,482	1.08 (0.71–1.66)
Lag-analysis, excluding the first 5 years of follow-up						
Aspirin use						
Nonuser	163	3,293,179	1.0 (—)	50	3,292,426	1.0 (—)
Any current use	172	2,783,718	0.75 (0.60–0.94)	51	2,783,146	0.82 (0.54–1.23)
Aspirin use, restricted to nonusers of other NSAIDs						
Nonuser	119	2,350,842	1.0 (—)	31	2,350,219	1.0 (—)
Any current use	84	1,879,068	0.62 (0.46–0.82)	31	1,878,714	1.03 (0.62–1.73)
Lag-analysis, excluding the first 10 years of follow-up						
Aspirin use						
Nonuser	66	1,596,930	1.0 (—)	20	1,596,605	1.0 (—)
Any current use	47	1,120,116	0.74 (0.50–1.08)	16	1,119,940	0.95 (0.48–1.85)
Aspirin use, restricted to nonusers of non-aspirin NSAIDs						
Nonuser	54	1,287,268	1.0 (—)	17	1,286,985	1.0 (—)
Any current use	34	932,565	0.70 (0.45–1.08)	13	932,410	0.98 (0.47–2.04)

NOTE: Adjusted for: sex, age (continuous), race (white, black, Asian/Pacific Islander, American Indian/Alaskan Native, other), cohort (AARP, AHS, USRT, PLCO, HPFS, CPSII, IWHS, BWHS, WHI, NHS), BMI (continuous), smoking status (nonsmoker, former smoker, current smoker), alcohol (nondrinker, and >0–<1, 1–3, >3 drinks/d), and history of diabetes (yes/no).

for anti-HCV and 3 (0.8%) were positive for HBsAg. In this nested case-control study, current aspirin use was associated with a 42% reduction in risk of HCC, compared with participants who did not use aspirin (HR, 0.58; 95% CI, 0.36–0.93). When further adjusted for HBsAg and anti-HCV status, the results were not substantially altered (HR, 0.60; 95% CI, 0.35–1.04).

Discussion

In the current study, we examined the association between aspirin and ibuprofen use and risk of HCC and ICC, stratified by dose, frequency, and duration of use. In our analyses, current aspirin use was associated with 32% lower risk of HCC. The inverse associations were robust in sensitivity analyses that excluded ibuprofen and other non-aspirin NSAID users and after excluding the NIH-AARP cohort, which made up about half of our cases. Among aspirin users who reported taking aspirin once daily, we found risk reductions for HCC of 32%. In addition in our study, aspirin use was associated with a 36% reduced risk of ICC in men but not women.

Three previous studies have reported an association between NSAID use and risk of liver cancer (23, 24, 32). In a previous study from the NIH-AARP cohort, any reported aspirin use in the 12 months prior to baseline was associated with a 41% decreased risk of HCC incidence and a 45% decreased risk of liver disease mortality (24). Across varying frequencies of aspirin use, risk reductions for HCC incidence were similar (24). In another U.S.-based case-control study, regular NSAID use (at least 4 d/wk for 3 months) was associated with a nonsignificant 10% reduction in liver cancer. However, this study was limited by a small number of cases ($n = 49$) (23). Finally, a Canadian population-based study of patients with rheumatoid arthritis treated with long-term NSAID therapy reported nearly twice the expected rate of liver or gall bladder cancer. However, these results were nonsignificant and based on only 5 observed cases (32). In addition, this study was focused on patients with rheumatoid arthritis that were actively being treated for their disease, which is very different population than individuals taking a daily aspirin for prevention purposes.

Similar to the previous study from the NIH-AARP cohort (24), we report homogeneous associations between aspirin use and HCC risk by sex. However, aspirin use among men, and not women, was associated with a reduced risk of ICC that was similar in magnitude to the association between aspirin use and HCC risk. Although the explanation of this is unclear, it could reflect etiologic differences between HCC and ICC or it could be a chance finding. In addition, we report that taking aspirin, on average, more than once daily or higher dosage aspirin (≥ 163 mg) was not associated with a decreased risk of HCC. Thus, individuals who chronically use high-dose aspirin may differ in important ways from those who use lower dose aspirin for cardiovascular benefits. Finally, in the group of participants reporting both aspirin and ibuprofen use, the possible converse association between aspirin use and HCC risk is potentially due to ibuprofen use interfering with the antiplatelet effects of aspirin (33).

Chronic inflammation is thought to contribute to the pathogenesis of both HCC and ICC (12, 13). Cyclooxygenase-2 (COX2), an enzyme that mediates inflammation and is usually expressed only at low levels in normal tissue, is overexpressed in response to a broad spectrum of proinflammatory stimuli, including those that mediate hepatic carcinogenesis (34). Overexpres-

sion of COX2 has been reported in premalignant, malignant, and metastatic HCC tissues, suggesting that COX2 may be involved several stages of hepatocarcinogenesis, beginning with the earliest stages of initiation. Similarly, COX1, an enzyme that is expressed in most normal tissue, has been reported to be more highly expressed in cirrhotic tissue compared with surrounding tissue and in well-differentiated HCC compared with poorly differentiated HCC (34). Such a result suggests that COX1 may also be involved in the early stages of tumor growth. In tumors, COX2 and possibly COX1 overexpression leads to increased prostaglandin levels, which can increase angiogenesis, cellular proliferation, and cell invasiveness and inhibit apoptosis (34). Aspirin and ibuprofen inhibit and modify both COX enzymatic pathways necessary for prostaglandin synthesis, thus inhibiting HCC cellular growth through cell-cycle arrest and induction of apoptosis (34). However, when aspirin and ibuprofen are taken concomitantly, ibuprofen interferes with the aspirin binding of platelet COX1 via competitive inhibition or by inducing conformational changes in the COX1 enzyme that slows down the rate of acetylation by aspirin (35, 36). Aspirin and ibuprofen may also modulate hepatocarcinogenesis through non-COX pathways, such as mitogen-activated protein kinase and PI3K/Akt pathways (21, 37), or downregulation of proinflammatory cytokines (38). While aspirin and ibuprofen are thought to act through similar mechanistic pathways, we may not see an association between ibuprofen use and HCC risk due to the fact that ibuprofen has a much shorter antiplatelet effect duration (a few hours) compared with aspirin (7–10 days; ref. 39). Low-dose aspirin does not work through the conventional COX pathways or downregulation of proinflammatory cytokines. However, research suggests that low-dose aspirin has anti-inflammatory properties in humans, through triggering 15-epi-lipoxin A₄ synthesis and ALX expression (40).

In an experimental study, aspirin decreased inflammation, fibrosis severity, and HCC progression in a mouse model of chronic HBV immune-mediated HCC but not when HCC was nonimmunologically induced (41). Thus, NSAIDs may differentially impact risk for viral and nonviral hepatocarcinogenesis. While the current study was adjusted for several major confounders, including alcohol consumption, obesity, and diabetes, we were unable to assess HBV and HCV status of all individuals. However, within the nested case-control study with information on HBsAg and anti-HCV status, results were not altered.

This study is susceptible to residual confounding for several reasons. We considered the possibility of a healthy-user bias, whereby individuals that consistently engage in beneficial behaviors (e.g., daily aspirin use to reduce risk of cardiovascular disease) may be fundamentally different from individuals that do not (42). Thus, aspirin use may reflect a healthier lifestyle in general. However, when results were stratified by smoking or alcohol consumption, we did not observe any notable differences. Furthermore, the use of other concomitant medications (e.g., statins), which may confound the association between aspirin use and liver cancer (43, 44), was also not assessed in this analysis. Confounding by indication is also a concern in the present study, as patients at highest HCC risk (e.g., those with cirrhosis and portal hypertension with thrombocytopenia) may be advised to avoid aspirin use due to risk of gastrointestinal bleeding and renal failure (45). However, we did not have information on preexisting liver disease. Thus, additional research is needed to examine whether aspirin use is inversely associated with risk among individuals without preexisting liver disease.

Several additional limitations should also be noted. All data on aspirin and non-aspirin NSAIDs were based on self-report at baseline interview and are subject to measurement error. In addition, data on dosage, duration, frequency, and time-varying change in use were not captured consistently in the questionnaires of the contributing studies. As aspirin use for the prevention of colorectal cancer is subject to duration (46), further research is needed to determine whether liver cancer has a similar necessary lag time before observing beneficial effects. Our lag analysis did not note any differences for when outcomes in the first 5 and 10 years were excluded, but for the studies with duration information, there was a nonsignificant decreased risk for more than 5 years of aspirin use. More research is also needed on the time-varying change in aspirin use. Participants may also alter their aspirin use during follow-up. Thus, the parent studies may have introduced measurement error by not assessing aspirin use repeatedly. Finally, these results may not be generalizable to non-white, younger, or Hispanic populations, as the cohorts included in our analysis were primarily composed of white, older age, non-Hispanic participants.

This study had a large sample size to evaluate the association between aspirin and ibuprofen use and liver cancer incidence by the two major subtypes, HCC and ICC. Although, the case numbers for ICC in this pooled analysis were limited. The large sample size of the LCPP, compared with previous studies, also allowed us to investigate potential effect modification by sex, smoking, and alcohol consumption; however, the number of cases for the stratified analyses is still relatively small. Finally, questionnaires used in these studies allowed participants' to self-report use of OTC products like aspirin and ibuprofen that are likely to be incompletely ascertained in studies based on medical records or prescription databases.

In conclusion, our finding of an inverse association between aspirin use and HCC, and possibly ICC among men, suggests that aspirin may reduce the risk of HCC and ICC in the United States. Further research is needed to elucidate the role of aspirin use, specifically frequency, duration, dosage, and combinations of these factors, in relation to HCC and ICC in the United States. In particular, our results suggest the need for intervention trials which assess the potential role of aspirin and other agents in the modulation of HCC, ICC, and related endpoints.

References

- Howlander N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER cancer statistics review, 1975-2011, Bethesda, MD: National Cancer Institute. [cited 2014 Apr] Available from: http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site.
- Ferlay J, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. [cited 2014 Jun 2] Available from: <http://globocan.iarc.fr>.
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. *CA Cancer J Clin* 2012;62:10-29.
- McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. *Clin Liver Dis* 2011;15:223-43, vii-x.
- El-Serag HB. Hepatocellular carcinoma. *N Engl J Med* 2011;365:1118-27.
- Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. *CA Cancer J Clin* 2012;62:118-28.
- Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. *J Clin Oncol* 2009;27:1485-91.
- Spangenberg HC, Thimme R, Blum HE. Advances in prevention and diagnosis of hepatocellular carcinoma. *Expert Rev Gastroenterol Hepatol* 2008;2:425-33.
- Altekruse SF, Devesa SS, Dickie LA, McGlynn KA, Kleiner DE. Histological classification of liver and intrahepatic bile duct cancers in SEER registries. *J Registry Manag* 2011;38:201-5.
- Ambade A, Mandrekar P. Oxidative stress and inflammation: essential partners in alcoholic liver disease. *Int J Hepatol* 2012;2012:853175.
- Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. *J Hepatol* 2012;57:69-76.
- Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. *Cell* 2010;140:883-99.
- Kumar M, Zhao X, Wang XW. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? *Cell Biosci* 2011;1:5.

Disclosure of Potential Conflicts of Interest

A.R. Hollenbeck is a consultant/advisory board member of Love/Avon Army of Women Scientific Advisory Board in the Society of Psychologists in Management Board of Directors. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: J.L. Petrick, V.V. Sahasrabudde, N.D. Freedman, A. Zeleniuch-Jacquotte, P.T. Campbell, K.A. McGlynn
Development of methodology: J.L. Petrick, V.V. Sahasrabudde, J. Michael Gaziano, B.I. Graubard, P.T. Campbell, K.A. McGlynn
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J.L. Petrick, A.T. Chan, M.C. Alavanja, J.E. Buring, N.D. Freedman, C.S. Fuchs, J. Michael Gaziano, A.R. Hollenbeck, E.J. Jacobs, I.-M. Lee, M.S. Linet, J.R. Palmer, M.P. Purdue, L. Rosenberg, C. Schairer, H.D. Sesso, A.J. Sigurdson, J. Wactawski-Wende, A. Zeleniuch-Jacquotte, P.T. Campbell
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J.L. Petrick, V.V. Sahasrabudde, A.T. Chan, J. Chen, E. Giovannucci, B.I. Graubard, E.J. Jacobs, H.D. Sesso, A. Zeleniuch-Jacquotte, P.T. Campbell, K.A. McGlynn
Writing, review, and/or revision of the manuscript: J.L. Petrick, V.V. Sahasrabudde, A.T. Chan, M.C. Alavanja, L.E. Beane-Freeman, J.E. Buring, D.Q. Chong, N.D. Freedman, C.S. Fuchs, E. Giovannucci, B.I. Graubard, A.R. Hollenbeck, L. Hou, E.J. Jacobs, L.Y. King, J. Koshiol, I.-M. Lee, M.S. Linet, J.R. Palmer, M.P. Purdue, H.D. Sesso, A.J. Sigurdson, J. Wactawski-Wende, A. Zeleniuch-Jacquotte, P.T. Campbell, K.A. McGlynn
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J.L. Petrick, V.V. Sahasrabudde, L.E. Beane-Freeman, D.Q. Chong, J. Michael Gaziano, I.-M. Lee, J. Wactawski-Wende, P.T. Campbell
Study supervision: V.V. Sahasrabudde, I.-M. Lee, K.A. McGlynn

Grant Support

The study was supported by NIH Intramural Research Program, National Cancer Institute (J.L. Petrick, V.V. Sahasrabudde, M.C. Alavanja, L. Beane-Freeman, J. Chen, N.D. Freedman, B.I. Graubard, J. Koshiol, M.S. Linet, C. Schairer, A.J. Sigurdson, K.A. McGlynn). National Cancer Institute Grants CA047988 (I. Lee, J.E. Buring), HL043851 (I. Lee, J.E. Buring), HL080467 (I. Lee, J.E. Buring), HL099355 (I. Lee, J.E. Buring), DK098311 (A.T. Chan), CA186107 (A.T. Chan), CA87969 (A.T. Chan), and CA167552 (A.T. Chan).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 30, 2015; revised August 31, 2015; accepted September 7, 2015; published OnlineFirst September 21, 2015.

14. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. *Lancet Oncol* 2009;10:501–7.
15. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: a summary review to 2007. *Recent Results Cancer Res* 2009;181:231–51.
16. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. *Lancet* 2011;377:31–41.
17. Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. *Cancer Prev Res* 2012;5:164–78.
18. Shebl FM, Hsing AW, Park Y, Hollenbeck AR, Chu LW, Meyer TE, et al. Non-steroidal anti-inflammatory drugs use is associated with reduced risk of inflammation-associated cancers: NIH-AARP study. *PLoS One* 2014;9:e114633.
19. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. *J Natl Cancer Inst* 2007;99:608–15.
20. Fodera D, D'Alessandro N, Cusimano A, Poma P, Notarbartolo M, Lampiasi N, et al. Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. *Ann N Y Acad Sci* 2004;1028:440–9.
21. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. *Hepatology* 2003;38:756–68.
22. Cervello M, Foderaa D, Florena AM, Soresi M, Tripodo C, D'Alessandro N, et al. Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis. *World J Gastroenterol* 2005;11:4638–43.
23. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, et al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. *Cancer Epidemiol Biomarkers Prev* 2000;9:119–23.
24. Sahasrabudhe VV, Gunja MZ, Graubard BI, Trabert B, Schwartz LM, Park Y, et al. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. *J Natl Cancer Inst* 2012;104:1808–14.
25. McGlynn KA, Sahasrabudhe VV, Campbell PT, Graubard BI, Chen J, Schwartz LM, et al. Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among U.S. women: results from the Liver Cancer Pooling Project. *Br J Cancer* 2015;112 Suppl:1266–72.
26. Kleinbaum D. *Logistic regression: a self-learning text second ed.* New York: Springer; 2002.
27. Rothman KJ, Greenland S, Lash TL. *Modern epidemiology.* 3rd ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008.
28. Dales LG, Ury HK. An improper use of statistical significance testing in studying covariables. *Int J Epidemiol* 1978;7:373–5.
29. Kleinbaum DG, Klein M. *Survival analysis: a self-learning text.* 3rd ed. New York: Springer; 2012.
30. Machin D, Cheung YB, Parmar MKB, Parmar MKB. *Survival analysis: a practical approach.* 2nd ed. Chichester, England; Hoboken, NJ: Wiley; 2006.
31. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.
32. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. *Arthritis Rheum* 1997;40:1580–6.
33. Food, Drug Administration USDoH, Human S. Concomitant use of ibuprofen and aspirin. *J Pain Palliat Care Pharmacother* 2007;21:73–4.
34. Cervello M, Montalto G. Cyclooxygenases in hepatocellular carcinoma. *World J Gastroenterol* 2006;12:5113–21.
35. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. *N Engl J Med* 2001;345:1809–17.
36. Hohlfeld T, Saxena A, Schror K. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs—pharmacological mechanisms and clinical relevance. *Thromb Haemost* 2013;109:825–33.
37. Kern MA, Schubert D, Sahi D, Schoneweiss MM, Moll I, Haugg AM, et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. *Hepatology* 2002;36:885–94.
38. Vaish V, Sanyal SN. Chemopreventive effects of NSAIDs on cytokines and transcription factors during the early stages of colorectal cancer. *Pharmacol Rep* 2011;63:1210–21.
39. Daniel N, Goulet J, Bergeron M, Paquin R, Landry P. Antiplatelet drugs: is there a surgical risk? *J Can Dent Assoc* 2002;68:683–7.
40. Morris T, Stables M, Hobbs A, de Souza P, Colville-Nash P, Warner T, et al. Effects of low-dose aspirin on acute inflammatory responses in humans. *J Immunol* 2009;183:2089–96.
41. Sitia G, Aiolfi R, Di Lucia P, Mainetti M, Fiocchi A, Mingozzi F, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. *Proc Natl Acad Sci U S A* 2012;109:E2165–72.
42. Kim AK, Dziura J, Strazzabosco M. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma: the egg of columbus or another illusion? *Hepatology* 2013;58:819–21.
43. McGlynn KA, Divine GW, Sahasrabudhe VV, Engel LS, VanSlooten A, Wells K, et al. Statin use and risk of hepatocellular carcinoma in a U.S. population. *Cancer Epidemiol* 2014;38:523–7.
44. McGlynn KA, Hagberg K, Chen J, Graubard BI, London WT, Jick S, et al. Statin use and risk of primary liver cancer in the clinical practice research datalink. *J Natl Cancer Inst* 2015;107.pii: djv009.
45. Singh S, Singh PP, Roberts LR, Sanchez W. Chemopreventive strategies in hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol* 2014;11:45–54.
46. Garcia-Albeniz X, Chan AT. Aspirin for the prevention of colorectal cancer. *Best Pract Res Clin Gastroenterol* 2011;25:461–72.